文献速递临床试验与 GCP

舍曲林治疗孤独症成人焦虑(STRATA):一项实用性、多中心、双盲、安慰剂对照随机对照试验的研究方案

Sertraline for anxiety in adults with a diagnosis of autism (STRATA): study protocol for a pragmatic, multicentre, double-blind, placebo-controlled randomised controlled trial.
PubMed 文献 · Trials · 2024-01-11

STRATA是一项两组平行、多中心、实用性、双盲、安慰剂对照的随机对照试验,计划在英国4个区域中心和澳大利亚1个中心招募孤独症成人,筛查时广泛性焦虑障碍量表(GAD-7)评分≥10者按1:1随机分配至舍曲林25 mg或安慰剂,随后灵活滴定至最高200 mg,主要结局为随机化后16周GAD-7评分,旨在评估舍曲林减轻焦虑症状、改善生活质量的效果与成本效果并量化不良反应。

要点

  • STRATA纳入孤独症成人且筛查时GAD-7评分≥10者,按1:1随机分配至舍曲林25 mg或安慰剂。
  • 舍曲林从25 mg起始,后续灵活滴定至最高200 mg,主要结局为随机化后16周GAD-7评分。
  • 次要结局包括不良反应、GAD-7评分比例变化(含50%下降)、社交焦虑、强迫症状、惊恐发作、重复行为、情绪崩溃、抑郁症状、功能与残疾及生活质量。

核心结论

  • 该研究旨在确定舍曲林与安慰剂相比在减轻孤独症成人焦虑症状和改善生活质量方面的有效性及成本效果,并量化任何不良反应。

研究设计与样本

  • STRATA是一项两组平行、多中心、实用性、双盲、随机安慰剂对照试验,按个体水平进行分配。
  • 试验通过英国4个区域中心和澳大利亚1个中心的孤独症服务招募点实施。
  • 纳入标准为孤独症诊断且筛查时广泛性焦虑障碍评估(GAD-7)评分≥10的成人,按1:1随机分配至舍曲林25 mg或安慰剂,随后灵活滴定至最高200 mg。
  • 主要结局为随机化后16周GAD-7评分;次要结局包括不良反应、GAD-7评分比例变化(含50%下降)、社交焦虑、强迫症状、惊恐发作、重复行为、情绪崩溃、抑郁症状、抑郁与焦虑复合评分、功能与残疾及生活质量。
  • 结局数据根据参与者偏好通过视频通话、面对面或电话以在线/纸质方式在随机化后16、24和52周收集,并在第1-2、4、8、12和36周进行简要安全性检查与数据收集;照护者负担在关联的照护者子研究中评估。

临床怎么用

  • 原文未据此给出推荐;作者在讨论中指出,该研究结果应有助于孤独症成人及其临床医生就使用舍曲林管理该人群焦虑做出循证决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed to manage anxiety in adults with an autism diagnosis. However, their effectiveness and adverse effect profile in the autistic population are not well known. This trial aims to determine the effectiveness and cost-effectiveness of the SSRI sertraline in reducing symptoms of anxiety and improving quality of life in adults with a diagnosis of autism compared with placebo and to quantify any adverse effects. METHODS: STRATA is a two-parallel group, multi-centre, pragmatic, double-blind, randomised placebo-controlled trial with allocation at the level of the individual. It will be delivered through recruiting sites with autism services in 4 regional centres in the United Kingdom (UK) and 1 in Australia. Adults with an autism diagnosis and a Generalised Anxiety Disorder Assessment (GAD-7) score ≥ 10 at screening will be randomised 1:1 to either 25 mg sertraline or placebo, with subsequent flexible dose titration up to 200 mg. The primary outcome is GAD-7 scores at 16 weeks post-randomisation. Secondary outcomes include adverse effects, proportionate change in GAD-7 scores including 50% reduction, social anxiety, obsessive-compulsive symptoms, panic attacks, repetitive behaviours, meltdowns, depressive symptoms, composite depression and anxiety, functioning and disability and quality of life. Carer burden will be assessed in a linked carer sub-study. Outcome data will be collected using online/paper methods via video call, face-to-face or telephone according to participant preference at 16, 24 and 52 weeks post-randomisation, with brief safety checks and data collection at 1-2, 4, 8, 12 and 36 weeks. An economic evaluation to study the cost-effectiveness of sertraline vs placebo and a QuinteT Recruitment Intervention (QRI) to optimise recruitment and informed consent are embedded within the trial. Qualitative interviews at various times during the study will explore experiences of participating and taking the trial medication. DISCUSSION: Results from this study should help autistic adults and their clinicians make evidence-based decisions on the use of sertraline for managing anxiety in this population. TRIAL REGISTRATION: ISRCTN, ISRCTN15984604 . Registered on 08 February 2021. EudraCT 2019-004312-66. ANZCTR ACTRN12621000801819. Registered on 07 April 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Rai D, Webb D, Lewis A, et al. Sertraline for anxiety in adults with a diagnosis of autism (STRATA): study protocol for a pragmatic, multicentre, double-blind, placebo-controlled randomised controlled trial. Trials. 2024. PMID: 38212784. doi:10.1186/s13063-023-07847-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。